<DOC>
	<DOC>NCT01188655</DOC>
	<brief_summary>This observational study will be a documentation of the prescribing and administration practices of Enbrel® and their impact on ankylosing spondylitis patients outcome in a real life setting.</brief_summary>
	<brief_title>Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description>The study population will be described using standard descriptive statistics for demographic, clinical, medical, characteristics, as well as for standard health-related quality of life and functional disability questionnaires .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Proven diagnosis of Ankylosing Spondylitisin accordance with local guidelines Patients treated as an outpatient Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®. Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localised infections. Patients with sepsis or risk of sepsis should not be treated.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>